X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs GLENMARK PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD GLENMARK PHARMA LUPIN LTD/
GLENMARK PHARMA
 
P/E (TTM) x 28.9 25.8 111.9% View Chart
P/BV x 3.0 4.0 74.7% View Chart
Dividend Yield % 0.6 0.3 184.1%  

Financials

 LUPIN LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
GLENMARK PHARMA
Mar-17
LUPIN LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,465993 147.5%   
Low Rs727729 99.7%   
Sales per share (Unadj.) Rs349.6325.5 107.4%  
Earnings per share (Unadj.) Rs5.639.3 14.1%  
Cash flow per share (Unadj.) Rs29.648.7 60.8%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.50.2 196.4%  
Book value per share (Unadj.) Rs300.3159.2 188.6%  
Shares outstanding (eoy) m452.08282.17 160.2%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x3.12.6 118.5%   
Avg P/E ratio x197.221.9 899.8%  
P/CF ratio (eoy) x37.117.7 209.4%  
Price / Book Value ratio x3.65.4 67.5%  
Dividend payout %90.05.1 1,767.5%   
Avg Mkt Cap Rs m495,502242,991 203.9%   
No. of employees `00017.013.0 131.4%   
Total wages/salary Rs m28,64716,408 174.6%   
Avg. sales/employee Rs Th9,273.67,083.9 130.9%   
Avg. wages/employee Rs Th1,681.01,265.4 132.8%   
Avg. net profit/employee Rs Th147.4855.1 17.2%   
INCOME DATA
Net Sales Rs m158,04291,857 172.1%  
Other income Rs m1,504374 402.4%   
Total revenues Rs m159,54592,230 173.0%   
Gross profit Rs m31,47520,367 154.5%  
Depreciation Rs m10,8592,644 410.7%   
Interest Rs m2,0442,373 86.1%   
Profit before tax Rs m20,07615,724 127.7%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644-810 1,809.0%   
Tax Rs m2,8853,827 75.4%   
Profit after tax Rs m2,51311,088 22.7%  
Gross profit margin %19.922.2 89.8%  
Effective tax rate %14.424.3 59.0%   
Net profit margin %1.612.1 13.2%  
BALANCE SHEET DATA
Current assets Rs m122,09568,746 177.6%   
Current liabilities Rs m50,95627,027 188.5%   
Net working cap to sales %45.045.4 99.1%  
Current ratio x2.42.5 94.2%  
Inventory Days Days8585 99.5%  
Debtors Days Days12096 125.5%  
Net fixed assets Rs m129,87624,132 538.2%   
Share capital Rs m904282 320.4%   
"Free" reserves Rs m134,86644,643 302.1%   
Net worth Rs m135,77144,925 302.2%   
Long term debt Rs m64,24545,363 141.6%   
Total assets Rs m263,054117,639 223.6%  
Interest coverage x10.87.6 142.0%   
Debt to equity ratio x0.51.0 46.9%  
Sales to assets ratio x0.60.8 76.9%   
Return on assets %1.711.4 15.1%  
Return on equity %1.924.7 7.5%  
Return on capital %3.719.1 19.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14156,152 94.6%   
Fx outflow Rs m19,3358,084 239.2%   
Net fx Rs m33,80748,068 70.3%   
CASH FLOW
From Operations Rs m17,5126,574 266.4%  
From Investments Rs m-14,073-7,124 197.6%  
From Financial Activity Rs m-14,9215,432 -274.7%  
Net Cashflow Rs m-11,4821,992 -576.3%  

Share Holding

Indian Promoters % 46.6 48.3 96.5%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 31.9 34.4 92.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 10.5 96.2%  
Shareholders   98,259 56,727 173.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Sep 19, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS